Latest News and Press Releases

Austin, TX, USA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Laboratory Informatics Market Size, Trends and Insights By Product (Laboratory...

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate...

Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock,...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer,...

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2...

- Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch- Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging ...

Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond...

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo®...

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic...

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated...

Entrada Therapeutics reports financial results for the fourth quarter and full year ended December 31, 2025, and highlights recent business updates.

AtaiBeckley today announced topline results from its Phase 2a study evaluating EMP‑01 (oral R‑MDMA) in adults with Social Anxiety Disorder.

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of...

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on...

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03...

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Pediatric Cancer Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Personalized Medicine Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Renal Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...

Healthcare predictive analytics to surge from USD 20.57 Billion in 2025 to USD 140.02B by 2035, driven by AI adoption, value-based care, and EHR expansion.

Ghent, Belgium, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Leading US liver transplant center completes its first two implantationsMount Sinai Hospital and University of Pennsylvania also complete multiple...

Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.Focused...

Charlotte,NC, Feb. 26, 2026 (GLOBE NEWSWIRE) --  Sarasota Magazine, an independent US-based media outlet, recently released its “Best THC Gummies Rankings - 2026”, placing Budpop’s THC edibles at...

Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics...

NEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a...

NEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a...

Informational overview of Sprout Health's compounded GLP-1 telehealth model, semaglutide and tirzepatide pricing, and FDA status for 2026.

Informational overview of MEDVi's compounded tirzepatide GLP-1 telehealth weight loss program, regulatory classification, and pricing disclosures.

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...

Informational overview of MEDVi QUAD's compounded ED prescription model, FDA framework, telehealth structure, and enrollment considerations.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options If you purchased or...

ACTG today announced the publication of “Tecovirimat for the Treatment of Mpox (STOMP)" in NEJM.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or...

Ra’anana, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira  Technologies” or the “Company”), a pioneer in innovative life-support and...

The lawsuit alleges that defendants failed to disclose that the FDA raised concerns about the adequacy of evidence supporting relacorilant’s NDA.

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of...

OraSure Announces Fourth Quarter 2025 Financial Results

ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and...

On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3...

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter...

Arcutis today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or...